Groundbreaking i-SIGHT2 Study Introduces Noninvasive Therapy for AMD Patients in the U.S.#United_States#Fort_Worth#i-Lumen_Scientific#AMD_Study#Bioelectric_Therapy
Groundbreaking i-SIGHT2 Study Introduces Noninvasive Therapy for AMD Patients in the U.S.
i-Lumen Scientific has announced that the first patient in the U.S. has been randomized in the i-SIGHT2 pivotal study for dry AMD, marking a significant step in treating retinal diseases.
third-news.com
July 21, 2026 at 1:31 PM
Groundbreaking i-SIGHT2 Study Introduces Noninvasive Therapy for AMD Patients in the U.S.#United_States#Fort_Worth#i-Lumen_Scientific#AMD_Study#Bioelectric_Therapy